October 12, 2023 01:04 PM EDT
Pharma

Pfiz­er ex­pands la­bel for block­buster BRAF/MEK com­bo in­to lung can­cer

Katherine Lewin

News Reporter

Pfiz­er’s $11.4 bil­lion 2019 ac­qui­si­tion of Ar­ray Bio­Phar­ma and its can­cer drugs Braftovi and Mek­tovi is pay­ing off again, this time with an ex­pand­ed la­bel …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times